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Abstract
Tumors are considered to be possible targets of immuno-
therapy using stimulated and expanded autologous or
allogeneic natural killer (NK) cells mismatched for MHC
class I molecules and inhibitory NK receptors. NK cell–
based immunoadjuvant therapies are carried out in
combination with standard chemotherapeutic protocols.
In the presented study, we characterized the effect of 28
frequently used chemotherapeutic agents on the capacity
of NK cells to kill target cells. We found that treatment of
NK cells with the drugs vinblastine, paclitaxel, docetaxel,
cladribine, chlorambucil, bortezomib, and MG-132 effec-
tively inhibited NK cell–mediated killing without affecting
the viability of NK cells. On the other hand, the following
drugs permitted efficient NK cell–mediated killing even at
concentrations comparable with or higher than the
maximally achieved therapeutic concentration in vivo in
humans: asparaginase, bevacizumab, bleomycin, doxoru-
bicin, epirubicin, etoposide, 5-fluorouracil, hydroxyurea,
streptozocin, and 6-mercaptopurine. [Mol Cancer Ther
2007;6(2):644–54]
Introduction
The goal of immune-based adjuvant therapeutic strategies
is to stimulate immune effector cells to kill malignant cells,
which may result in a better clinical outcome. Infiltration of
solid tumors with inflammatory cells is a well-known
phenomenon (1–3). Several studies showed that the
infiltration of natural killer (NK) cells in malignant tumors
was associated with a better clinical outcome (4, 5).
NK cells are large granular lymphocytes that are part of
the innate immune system (6). Mature NK cells are mostly
circulating in the peripheral blood, where they represent
f10% to 15% of all blood lymphocytes. Phenotypically, NK
cells express surface antigen CD56, which has unknown
function on NK cells, and lack the typical T-cell antigen
CD3 (7). Physiologically, NK cells have direct cytotoxic
activity against tumor targets and virus-infected cells (8).
NK cells can regulate adaptive immune response by IFN-g
production and can mediate antibody-dependent cellular
toxicity through membrane FcgRIII (CD16; ref. 6). These
cells have the ability to directly kill target cells and produce
immunoregulatory cytokines in transfused cancer patients
(9–12).
The outcome of NK cell-target cell interactions is
regulated by a fine integrative balance between inhibitory
and activating receptors; the first elicited by the recogni-
tion of MHC class I molecules by NK inhibitory receptors
(killer immunoglobulin– like receptors, CD94/NKG2A,
and immunoglobulin-like transcript) and the latter by NK
cell–activating (NKG2D and natural cytotoxicity receptor)
receptors that can sense stress inducible glycoprotein
(MHC class I chain–related proteins and UL16 binding
proteins) expression on tumor- and virus-infected target
cells (13). Because NK cells are able to spontaneously lyse
tumor cells, considerable effort has been focused on
investigating the possible use of NK cells in the treatment
of human cancer. Recent understanding of NK cell
development and function has permitted the investigation
of novel NK cell–based immunotherapeutic modalities. A
promising approach is to expand allogeneic NK cell clones
in vitro , with typed killer immunoglobulin–like receptor
expression, and to transfuse these cells into leukemic
patients (14–16).
Basse et al. (17) showed that the level of accumulation of
NK cells in murine tumor metastases in vivo is dependent
on the dose and frequency of interleukin 2 (IL-2)
administration. NK cells have also been used in human
therapeutic regimens that involved the administration of
high or low doses of IL-2, alone or in combination with
IL-2–activated blood lymphocytes or purified populations
of NK cells, for primary lung and renal cell carcinomas
(18, 19). In other studies, extended low-dose IL-2 was used
to activate NK cells in patients with solid tumors who
received intensive chemotherapy or in patients with acute
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myeloid leukemia (20, 21). Harker et al. (22) suggested
that IL-2–induced lymphokine-activated killer cells may
be useful in the treatment of chemotherapy-resistant
cancers.
The chemotherapeutic regimens for malignancies restrict
the effectivity of the immune system and significantly
decrease the level of NK cells (23). The activity of NK cells
is also affected by some cytostatic drugs (24). Utsugi et al.
(25) observed enhanced NK cell–mediated cytotoxicity
following treatment of the target cells with topoisomerase
inhibitors. Killing by NK cells requires microtubule
integrity, which may be influenced by antimicrotubule
agents (26). It is important to consider the drug-induced
effects when chemotherapy and NK cell–mediated immu-
notherapy are planned to be used in parallel.
The aim of this study was to systematically investigate
the effect of the most frequently used cytostatic drugs on
NK cell–mediated cytotoxicity. We carried out more than
4,000 cell survival assays on single-cell levels using
automated laser confocal microscopy to establish the
pattern of in vitro effect of 29 different cytotoxic drugs on
the efficiency of NK cell–mediated killing.
Materials andMethods
IsolationandCulturingofHumanPolyclonalPeripheral
BloodNKCell Cultures
Polyclonal NK cells were acquired from lymphocyte-
enriched buffy coat derived from healthy donor blood
(Blodbank, Karolinska Sjukhuset, Stockholm). Peripheral
blood mononuclear cells were isolated by centrifugation on
Lymphoprep (Axis-Shield, Oslo, Norway). NK cells were
isolated from peripheral blood mononuclear cells by
negative magnetic bead selection (Stemcell Technologies,
Vancouver, Canada) according to the manufacturer’s
instructions. Purified NK cells were >95% CD3CD56+.
NK cells were cultured either overnight or for several
weeks in IMDM supplemented with 10% human serum
(AB, Blodbank), 2 mmol/L L-glutamine, 1 nonessential
amino acids, 1 mmol/L sodium pyruvate, 50 units/mL
penicillin-streptomycin, 50 Amol/L 2-mercaptoethanol (me-
dia and supplements bought from Life Technologies, Inc.,
Carlsbad, CA), and 100 units/mL IL-2 (Peprotech, Inc.,
London, United Kingdom).
Eight primary NK cell isolates were tested in the present
study. Five NK cell isolates were restimulated every 3 to
Figure 1. Time-lapse image sequence of NK cells
killing a K562 target cell. Target cells were labeled with
CellTracker green (CMFDA; Invitrogen). NK cells were
labeled with CellTracker blue (CMAC; Invitrogen). Dead
cells were labeled with ethidium bromide (red). Images
were taken with an automated laser confocal micro-
scope (a modified Perkin-Elmer UltraView LCI). Arrows,
green target cells as they get killed by the surrounding
NK cells and turn red. Time scale is given in seconds.
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4 days with fresh IL-2–containing media for 1 week and
were periodically monitored for the CD3CD56+ pheno-
type. Three NK cell isolates were stimulated with IL-2 only
for 24 h.
Cell Lines and Culture Conditions
Cytotoxic NK tumor cell lines Nishi (27), NKL (28), NK92
(29), and KHYG-1 (30) were cultured in IMDM supple-
mented with different concentrations of IL-2 (Nishi and
NK92, 100 units/mL; NKL, 200 units/mL; KHYG-1, 450
units/mL). K562 cell line was used as target in the in vitro
killing assay. These cells were cultured in IMDM (Sigma,
Dorset, United Kingdom) supplemented with 10% FCS
(Sigma), 100 mmol/L L-glutamine (Sigma), and 80 Ag/mL
gentamicin (Sigma). Cell suspensions were grown in a
humidified incubator at 37jC in an atmosphere containing
5% CO2. Cell counts were adjusted to 1  106/mL and the
cells were fed twice a week. The absence of Mycoplasma
contamination was ensured by regular monitoring with
Hoechst 33258 staining.
In vitro Killing Assay (StandardChromium-51Release
Assay)
Target cells were labeled for 1 h at 37jC, 7.5% CO2 with
100 ACi of Na251CrO4 (Amersham Biosciences, Uppsala,
Sweden) added directly to the cell pellet. Radioactively
labeled target cells were washed thrice with RPMI, and
15  103 cells were plated per well in flat-bottomed 96-well
microtiter plates to replicate cell densities in the flat-bottomed
microtiter plates. NK cells were subsequently added at 5:1
effector-to-target ratio per well (total volume of 200 AL/well)
and incubated for 5 h at 37jC, 5% CO2. Spontaneous release
was determined by incubation of labeled target cells with
media alone whereas maximal release was determined
Table 1. AUC values of the used drugs and calculated RAUC values for NK cells
Drug groups Drug name Brand name, company Concentrations with
NK cells alone (Ag/mL)
Topoisomerase
inhibitor effect
Anthracyclines Epirubicin Epirubicin Meda, Meda 0.02–2.5
Daunorubicin CerubidinR, Aventis Pharma 0.05–6.25
Doxorubicin Doxorubicin Teva, Teva 0.02–2.5
Epipodophyllotoxin Etoposide Sigma 0.244–31.25
Camptothecins Topotecan Hycamtin, GlaxoSmithKline 0.04–5
Microtubule inhibitors Taxanes Paclitaxel Taxol, Orifarm 0.06–7.5
Docetaxel TaxotereR, Aventis Pharma 0.4–50
Vinca alkaloids Vincristine Vincristine Mayne, Mayne Pharma 0.005–0.625
Vinblastine VelbeR, STADApharm 0.001–1.25
Vinorelbine NavelbineR, Pierre Fabre 0.098–12.5
Platinum analogues Carboplatin Carboplatin Mayne, Mayne Pharma 0.098–12.5
Oxaliplatin Eloxatin, Sanofi-Synthelabo 0.05–6.25
Antimetabolites Antifolate Methotrexate Methotrexate Pharmacia, Pfizer 0.244–31.25
Purine antagonists 6-Mercaptopurine Sigma 0.814–104.16
Cladribine Leustatin, Janssen-Cilag 0.01–1.25
Pyrimidine antagonists 5-Fluorouracil Fluorouracil Mayne, Mayne Pharma 0.488–62.5
Cytarabine Cytarabine Pfizer, Pfizer 0.977–125
Gemcitabine Gemzar, Orifarm 0.586–75
Antitumor antibiotics Bleomycin Bleomycin Baxter, Baxter 0.293–37.5*
Dactinomycin CosmegenR, MSD 0.005–0.625
Protease inhibitors Bortezomib VelcadeR, Janssen-Cilag 0.01–1.25
MG-132 Sigma 0.098–12.5
Alkylating agents Cyclophosphamide Sendoxan, Baxter 0.4–50
Ifosphamide HoloxanR, Baxter 0.4–50
Chlorambucil Sigma 0.977–125
Streptozocin Sigma 0.488–62.5
Miscellaneous Asparaginase Asparaginase Medac, Medac 0.05–6.25*
Hydroxyurea Sigma 0.488–62.5
Bevacizumab AvastinR, Roche 0.244–31.25
NOTE: Ratio of in vitro and in vivo AUC levels (RAUC) values were formed to calculate relationship between the in vitro drug concentrations and the clinical
doses. In vitro AUC values were determined using the following formula: in vitro used concentration (Ag/mL)  20 h.
*For bleomycin and asparaginase, the concentrations are in international units per milliliter.
cNot used in the clinical practice.
bNo data are available.
xGlaxoSmithKline Research Triangle Park N. Prescribing Information Leukeran. Available from: http://us.gsk.com/products/assets/us_leukeran.pdf.
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by lysis of target cells in 10% SDS. Spontaneous release
was <15% of the maximal release. One hundred microliters
of supernatant were collected for scintillation counting on
a g irradiation counter. Each measurement was done in
triplicate and the average of three wells was used for
calculation of specific lysis. Specific lysis (killing effective-
ness) was calculated as follows: killing effectiveness (%) =
[(cpm experimental well cpm spontaneous release) / (cpm
maximal release  cpm spontaneous release)]  100.
In vitro Killing Assay (Novel Fluorescent LabeledKill-
ing Assay)
The effects of drugs on in vitro killing efficacy of different
NK cell lines were assessed using microtiter plates.
Twenty-nine drugs were tested, each at four different
concentrations in triplicates on flat-bottomed 384-well
plates. Each well was loaded with 20-AL cell suspension
of NK cells containing 15,000 cells and was incubated for
20 h at 37jC in 5% of CO2. Target (K562) cells were stained
with CellTracker green CMFDA (Invitrogen, Sweden). A
time-lapse image sequence of NK cell killing of target cells
is illustrated in Fig. 1. As a next step, 20 AL of target cells
(K562) containing 3,000 cells were seeded on the same plate
and were incubated with the NK cells for 5 h (effector-to-
target ratio, 5:1). Dead cells were differentially stained red
with ethidium bromide. The precise numbers of green
target cells and red dead cells were determined by
fluorescent detection using a custom-designed automated
laser confocal fluorescent microscope (a modified Perkin-
Elmer UltraView LCI) at the Karolinska Institute visuali-
zation core facility. The images were captured using the
computer program QuantCapture 4.0, and the living and
dead target cells were identified and individually counted
using the computer program CytotoxCount 3.0. The target
cells were identified as dead if they were stained red and
green at the same time. Both programs were developed at
Karolinska Institute visualization core facility using Open-
Lab Automator programming environment (Improvision).
On each plate, eight wells were set up as controls to
determine the baseline killing activity. These wells
contained NK and K562 cells in culture medium only
(without drugs). As additional control, effector NK cells
alone were incubated under the same conditions. To
monitor the possible short-term effect on the target cells,
K562 cells were incubated alone and with all the individual
Table 1. AUC values of the used drugs and calculated RAUC values for NK cells (Cont’d)
Concentrations with
target cells together
(Ag/mL)
AUC in vivo
(Ag h/mL)
In vivo
dose (AUC)
References RAUC for NK cells
0.01–1.245 2.412 90 mg/m2 Fogli et al. (31) 0.17–20.65
0.02–3.125 1.2786 1.5 mg/kg Andersson et al. (32) 0.75–97.75
0.01–1.245 0.82464 50 mg/m2 Toffoli et al. (33) 0.5–60.4
0.12–15.625 5.06 100 mg/m2/d Gruber et al. (34) 0.97–123.52
0.02–2.5 0.0196 1.2 mg/m2/d Gerrits et al. (35) 39.85–5,101
0.03–3.75 13.49 175 mg/m2 Fogli et al. (31) 0.08–11.12
0.2–25 3.326 85 mg/m2 Rischin et al. (36) 2.35–301
0.003–0.312 0.182 1.32 mg/m2 Desai et al. (37) 0.5–68.67
0.005–0.625 0.218 1.7 mg/m2 Bates et al. (38) 0.9–114.6
0.05–6.25 0.899 80 mg/m2/wk Freyer et al. (39) 2.17–277.94
0.05–6.25 348000 360 mg/m2 Ghazal-Aswad et al. (40) 5.6  106–0.0008
0.025–3.125 71.5 130 mg/m2 Graham et al. (41) 0.02–1.75
0.12–15.625 13200000 12 g/m2 Crews et al. (42) 3.7  107–4.7  105
0.4–52.08 0.2587 85 mg/m2 Chan et al. (43) 62.8–8,052.57
0.005–0.625 0.1541 5 mg/m2 Albertioni et al. (44) 1.26–162.17
0.244–31.245 11.59 400 mg/m2 Casale et al. (45) 0.85–107.83
0.5–62.5 523.4 1 g/m2 Gruber et al. (34) 0.04–4.78
0.3–37.5 9.3 1,000 mg/m2 Fogli et al. (31) 1.25–161.3
0.15–18.75* 0.089* 8 IU/kg/d Peng et al. (46) 65.5–8,427
0.003–0.312 300 1.5 mg/m2 Veal et al. (47) 0.00033–0.0416
0.001–0.625 0.0438 1.45 mg/m2 Papandreou et al. (48) 4.45–571
0.05–6.25 c b
0.2–25 367 50 mg/kg Xie et al. (49) 0.02–2.72
0.2–25 1,827.7 3 g/m2/d Boddy et al. (50) 0.005–0.55
0.5–62.5 0.883 0.2 mg/m2 (GlaxoSmithKline
Research Triangle Park)x
22.12–2,831
0.24–31.245 b b
0.025–3.125* 0.943* 30.000 IU/m2 Ylikangas et al. (51) 1.04–132.53
0.24–31.245 82.49 15 mg/kg Yan et al. (52) 0.12–15.15
0.122–15.625 b b
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drugs for 5 h. Killing effectiveness of NK cells was
calculated for every well using the following formula:
[number of dead target cells (both red and green signal in
the same cell) / number of all (green) target cells]  100.
To normalize the killing effect values of different NK
populations, the following formula was used: (killing
effectiveness in the wells with drugs / mean killing
effectiveness values of the control wells)  100%. Mean
killing efficacy was determined from the average killing of
all NK populations. The red-stained cells that were not
green at the same time were considered as dead NK cells.
The cytotoxic effect (%) of the drugs on NK cells was
calculated with the following formula: (number of dead NK
cells in the wells with drugs / number of dead NK cells in
the control wells)  100%.
Drugs
For the in vitro killing test, 29 drugs were used
(summarized in Table 1). Twenty-eight of these drugs are
regularly used in the treatment of human patients. All the
drugs were dissolved in 50% DMSO and printed on 384-
well flat-bottomed plates using a high-density metal pin
array (50-nL replica volumes) in Biomek 2000 fluid
dispenser robot (Beckman, Fullerton, CA). The same robot
was used to generate the drug masterplates containing the
triplicates of four different drug dilutions using a single-tip
automatic dispenser head.
The highest drug concentration was selected as the maxi-
mum drug concentration physiochemically achievable at
600 dilution (50 nL of drug in a 30-AL assay volume). These
concentrations are in a comparable range with the in vivo
plasma concentrations in patients (31–52).5 The starting
concentrations of the dilution series (1, 5, 25, 125) for
the individual drugs were initially determined based on
the solubility of the different agents. The fifth to sixth rows
of Table 1 represent the drug concentrations that were pre-
sented in the wells with NK cells alone and after increasing
the volumes with 20-AL cell suspension of target cells.
Testing the drug plates on a large number of in vitro
tumor cell lines and primary tumors, it was possible to find
sensitive cell lines for each individual drugs, showing that
all the drugs on the plate were active (data not shown).
A way to calculate a relationship between the in vitro
drug concentrations and the in vivo ones is to use the area
under the curve (AUC) values of the individual drugs. For
this comparison, ratio of area under the curve (RAUC)
values were determined by the following formula: in vitro
used concentration (Ag/mL)  20 h/ AUC (Ag h/mL)
in vivo . A RAUC value >1 indicates that the in vitro used
dose is higher than the one used in clinical practice. If this
value is 1, it means that our in vitro dose corresponds to the
clinical dose. In vivo AUC levels, clinical doses, and
calculated RAUC values of the individual drugs from the
literature are summarized in Table 1. RAUC values are also
shown in Fig. 2.
Results
Comparison of the Novel In vitro Killing Assay to the
Standard Chromium-51ReleaseAssay
The two methods were compared with each other in the
absence of drugs under the same conditions (incubation
time, effector-to-target ratio, flat-bottomed plates instead of
V-bottomed plates). The results of our single-cell fluores-
cence method correlate closely to the standard chromium-51
release assay on different NK cell lines. Figure 3 shows the
in vitro killing capacity of a NK tumor cell line (NKL) and
two NK cell clones tested with both methods.
Effect of Drugs on the Killing Capacity of Different
NKCells
The eight different primary NK cell polyclonal prepa-
rations from healthy donors and four NK tumor cell lines
that were tested with the novel fluorescent method in the
present study represent a variety of cells with different
origin and in vitro history. The investigation included
separated NK cells from healthy donors with 1 week of
in vitro culturing together with IL-2 along with freshly
separated NK cells cultured with IL-2 only for 24 h. NK
tumor cell lines showed relatively low killing efficiency
(V10%) in our novel experimental model system. Micros-
copy evaluation of killing activity requires the use of flat-
bottomed plate instead of conventional V-bottomed
plates. Many of the NK tumor lines showed low
spontaneous mobility and required high-level cellular
crowding to be able to kill effectively. Control killing
effectiveness values for all investigated NK cell lines can
be seen in Table 2.
The NK cells of different origins showed a very similar
killing efficacy pattern in the presence of most of the drugs.
This phenomenon is illustrated in Fig. 4, summarizing the
killing effectiveness of all NK cell populations in the
presence of 29 drugs at four different concentrations. Each
individual thin curve represents the average of three
independent measurements. The thick broken line is the
mean of all curves, the mean killing efficacy. The curves
labeled by black spots are NK cell isolates, treated with
IL-2 only for 1 day. The gray shaded area marks the SD.
Figure 5 illustrates the cytotoxic effect (%) of all of the
drugs on NK cells, as shown in a similar way in Fig. 4.
All the mean killing efficacy values are represented in
Table 3. Importantly, none of the drugs influenced the
viability of the K562 target cells during the 5-h incubation
(data not shown). The number of dead NK cells in the
drug-treated cultures that received IL-2 only for 1 day was
higher than those in the drug-treated cultures that received
IL-2 for 1 week. None of the NK populations showed dose-
dependent increase in the number of dead cells. Conse-
quently, the dose-dependent decrease in the killing effect
of NK cells in case of certain drugs cannot be simply
explained by drug-induced NK cell death (Fig. 5).
Identification of Highly Effective and Noneffective
Drugs
We found that the most effective drugs that inhibited NK
cell–mediated killing were chlorambucil, MG-132, doce-
taxel, cladribine, paclitaxel, bortezomib, gemcitabine, and
5 GlaxoSmithKline Research Triangle Park N. Prescribing Information Leu-
keran. Available from: http://us.gsk.com/products/assets/us_leukeran.pdf.
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vinblastine (Fig. 4). For MG-132, no RAUC value could be
defined because this drug has not been clinically used.
Oxaliplatin, dactinomycin, cytarabine, daunorubicin, vin-
cristine, and topotecan were only marginally effective.
Most NK cell lines were not affected by bevacizumab,
bleomycin, doxorubicin, epirubicin, vinorelbine, carbopla-
tin, methotrexate, ifosphamide, etoposide, hydroxyurea,
asparaginase, 5-fluorouracil, 6-mercaptopurine, streptozo-
cin, and cyclophosphamide.
Discussion
In our experimental model, the killing effectiveness of NK
cells was tested in the presence of different cytostatic drugs.
Previous studies investigated NK cell–mediated cytotox-
icity following treatment of target cells with certain
cytotoxic drugs (25) or treatment of NK cells with a few
chemotherapeutic agents before the NK cell killing assays
(24, 26). No systematic study has been carried out to
investigate the effect of a large number of different drugs at
different concentrations.
In our experimental setup, the NK cells were preincu-
bated alone for 20 h with the drugs to test the drug effect
only on the NK cells. This was followed by coincubation
with the target cells for 5 h. No drug-induced cytotoxicity
was detectable on target cells during this incubation,
although other effects on target cells, which influence NK
cell killing, cannot be excluded.
The presented data suggest that IL-2–activated NK cell
lines share a common profile of cytotoxic drug sensitivity.
This profile does not change with different lengths of
in vitro culturing with IL-2.
Topotecan, 6-mercaptopurine, and bleomycin did not
inhibit NK cell killing effectively even at very high AUC
levels. Almost no effect could be seen in case of carboplatin,
methotrexate, and dactinomycin, although this might be
explained by the relatively low range of RAUC levels
achieved in the microcultures.
Although chlorambucil efficiently inhibited the killing
effect of NK cells, other alkylating agents like cyclophos-
phamide and ifosphamide did not affect NK cell killing. This
might be explained by the fact that both of the latter
compounds are prodrugs that have to be converted into
active metabolites by the liver in vivo .
The effectiveness of chlorambucil may also be explained
by the high in vitro RAUC levels (Fig. 2; Table 1). The
Figure 3. Comparing of the fluorescent in vitro killing assay to the
standard chromium-51 release assay. NKL cell line and two IL-2–activated
primary NK cell polyclonal preparations were incubated together with
K562 target cells for 5 h. Effector-to-target ratio was always 5:1. KE,
killing effectiveness.
Figure 2. RAUC values for NK cells (data are also represented in Table
1). To calculate relationship between the in vitro used drug concentrations
and the in vivo used values, RAUC values were determined by the
following formula: in vitro used concentration (Ag/mL)  20 h / AUC (Ag
h/mL) in vivo. RAUC> 1, the in vitro dose is higher than the clinical dose.
RAUC < 1, the in vitro dose is lower than the clinical dose. RAUC = 1,
the in vitro dose is corresponding to the clinical dose.
Table 2. Killing effectiveness of different NK cell lines
KE (%) SD
NK cells treated with IL-2 for 1 wk
Clone 1 27.93 5.01
Clone 2 64.16 8.49
Clone 3 77.47 14.27
Clone 4 20.92 2.5
Clone 5 24.61 4.92
NK cells treated with IL-2 for 1 d
Clone 1 55.99 4.67
Clone 2 41.05 3.56
Clone 3 31.83 7.01
NK tumor cell lines
Nishi 5.9 2.53
NKL 8.55 1.54
NK92 10.05 4.48
KHYG-1 9.94 3.06
Abbreviation: KE, killing effectiveness.
Molecular Cancer Therapeutics 649
Mol Cancer Ther 2007;6(2). February 2007
in vitro doses (in vitro AUC levels) of the other effective
drugs were in close vicinity to the clinical doses.
Unlike Reiter et al. (53) who found no inhibition of NK
cell killing ability when effector cells (NK cells) alone
were treated with cladribine, this agent was the only drug
among the base analogues that significantly decreased the
killing effect of IL-2–activated NK cells in our experi-
mental setup.
Our data also showed that NK cells are particularly
sensitive to antimicrotubule drugs and proteosome inhib-
itors. The dependence of NK cell–mediated killing on
microtubule integrity is well known (24, 26). Here we show
that different microtubule inhibitors have a variable effect
on NK cell–mediated killing. Vinorelbine and vincristine
had much less effect on NK cell–mediated killing than
vinblastine, docetaxel, or paclitaxel.
Several studies showed that the chymotryptic activity
of proteasomes in NK cells might play a role in their
cell-mediated cytotoxicity (54–56). Kitson et al. (54)
reported that synthetic proteasome inhibitors like CEP-
1508, CEP-1612, and CEP-3117 can inhibit the rat NK
proteasome in a dose-dependent manner and found a 50%
inhibition of IL-2–activated NK cell–mediated cytotoxicity.
Lu et al. (57) pointed out that MG-132 could reduce NK
Figure 4. Killing effectiveness of NK cells
tested with the fluorescent killing assay. The
figure summarizes the killing effectiveness
of all NK cell populations in the presence of
29 drugs at four different concentrations.
Thin curves, average of three independent
measurements. Thick broken line, mean of
all curves, the mean killing efficacy (MKE ).
Curves with black spots, NK cell isolates
that were treated with IL-2 only for 1 d. Gray
shaded area, SD. A, effective drugs (lowest
mean killing efficacy, <60%). B, marginally
effective drugs (lowest mean killing efficacy,
60–70%). C, noneffective drugs (lowest
mean killing efficacy, >70%). X axis,
increasing concentrations of the drug. Y
axis, killing effectiveness of NK cells 0% to
120%.
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cell–mediated cytotoxicity of rat NK cells, but this was due
to the apoptosis-inducing property of the drug. Here, we
show that proteosome inhibitors severely compromise the
killing efficiency of human NK cells even in the absence of
apoptosis induction.
Bortezomib is a clinically used reversible inhibitor of the
chymotrypsin-like activity of the 26S proteasome. A study
showed that bortezomib can sensitize tumor cells to the
lytic effects of dendritic cell–activated immune effector
cells like NK cells or CD8+ lymphocytes (58), but no data
have been published on the direct inhibition effect of
bortezomib on NK cell–mediated cytotoxicity.
Our results suggest that chemotherapy protocols that
include proteosome inhibitors or antimicrotubule drugs
may interfere with NK cell–based immunotherapy, if
applied simultaneously.
Table 3. Mean killing effectiveness of NK cells in the presence of different drugs
125
dilution
25
dilution
5
dilution
Highest
concentration
125
dilution
25
dilution
5
dilution
Highest
concentration
Epirubicin Paclitaxel
MKE (%) 98.52 87.28 85.24 79.66 MKE (%) 89.43 85.03 77.36 54.97
SD 11.45 20.67 22.28 21.91 SD 9.87 16.00 19.37 24.69
Daunorubicin Docetaxel
MKE (%) 92.29 87.61 83.01 68.43 MKE (%) 68.49 60.11 51.97 39.85
SD 18.22 22.09 24.92 30.94 SD 19.35 24.56 18.40 16.46
Doxorubicin Vincristine
MKE (%) 84.77 81.47 78.30 75.29 MKE (%) 85.61 82.92 72.76 69.32
SD 16.55 17.25 18.15 30.55 SD 20.38 19.56 18.43 20.86
Etoposide Vinblastine
MKE (%) 97.15 101.54 90.41 85.49 MKE (%) 94.98 95.51 83.78 58.15
SD 13.66 11.38 19.18 20.52 SD 9.66 12.13 18.38 16.69
Topotecan Vinorelbine
MKE (%) 81.25 79.76 72.78 69.60 MKE (%) 92.91 93.43 82.14 79.76
SD 14.95 23.82 21.74 28.46 SD 22.12 21.90 21.63 21.96
Methotrexate Carboplatin
MKE (%) 101.79 95.65 85.15 80.89 MKE (%) 90.87 89.36 85.42 80.62
SD 14.39 11.99 23.38 18.75 SD 23.03 25.56 34.35 25.91
6-Mercaptopurine Oxaliplatin
MKE (%) 99.16 103.02 95.28 92.25 MKE (%) 71.79 72.72 62.47 65.78
SD 14.60 12.08 14.46 17.24 SD 18.56 20.61 19.54 18.20
Cladribine Bleomycin
MKE (%) 89.87 81.83 56.65 47.66 MKE (%) 85.54 76.67 70.38 74.41
SD 12.89 14.85 12.82 18.89 SD 17.85 16.97 13.54 19.01
Fluorouracil Dactinomycin
MKE (%) 96.24 100.34 92.61 87.67 MKE (%) 95.06 87.14 75.95 67.18
SD 15.90 18.31 15.49 25.05 SD 17.25 17.06 21.22 23.69
Cytarabine Bortezomib
MKE (%) 87.38 89.48 76.69 68.42 MKE (%) 97.76 94.86 88.10 56.40
SD 15.52 11.12 20.15 28.22 SD 22.20 14.83 29.71 25.26
Gemcitabine MG-132
MKE (%) 83.92 74.97 60.22 58.12 MKE (%) 94.95 85.47 64.43 15.79
SD 17.96 19.41 19.41 25.37 SD 18.81 20.96 17.03 6.67
Cyclophosphamide Asparaginase
MKE (%) 100.39 95.74 91.91 93.40 MKE (%) 93.40 94.73 81.18 87.03
SD 6.79 19.12 17.13 18.21 SD 22.02 24.74 19.73 18.42
Ifosphamide Hydroxyurea
MKE (%) 99.42 95.93 94.26 83.80 MKE (%) 90.27 94.93 84.75 86.42
SD 7.06 9.50 15.95 16.78 SD 7.51 10.20 12.82 22.98
Chlorambucil Bevacizumab
MKE (%) 84.79 83.86 19.81 13.14 MKE (%) 86.96 80.60 75.82 74.41
SD 17.64 22.51 6.37 6.67 SD 15.19 14.59 18.07 18.46
Streptozocin
MKE (%) 96.02 99.77 95.52 93.34
SD 16.86 17.94 19.45 19.09
NOTE: Data were also used for preparing Fig. 4. MKE (%), mean killing effectiveness.
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Based on the almost complete absence of inhibitory effect
on NK cell–mediated killing even at high RAUC levels
(concentrations that are directly comparable with maxi-
mally achieved in vivo therapeutic doses), we suggest that
the following drugs may be effectively combined with
adjuvant NK cell–based immunotherapy: asparaginase,
bevacizumab, bleomycin, doxorubicin, epirubicin, etopo-
side, 5-fluorouracil, hydroxyurea, streptozocin, and
6-mercaptopurine.
Several anticancer drugs have been reported to induce
the expression of ligands for activating NK cell receptors on
the tumor cell membrane potentially increasing NK cell–
mediated cytotoxicity against tumor cells. This information,
in combination with the data presented here, could
potentially be used in the future to design new NK cell–
based adjuvant immunotherapy protocols.
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